Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events

28 Aug 2023
www.biospace.com
Cell Therapy
BOSTON--(BUSINESS WIRE)-- Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that company leadership will present and participate in the following investor and industry events: 8th Annual CAR-TCR Summit: Fireside chat on Wednesday, August 30, 2023, at 2:00 p.m. ET in Boston, MA with John Trzupek, M.B.A., Ph.D., Chief Operating Officer. Citi’s 18th Annual BioPharma Conference: Panel discussion on Wednesday, September 6, 2023, at 3:30 p.m. ET in New York, NY with Samantha Singer, M.S., M.B.A., President, and Chief Executive Officer. Chardan 2nd Annual SPICI Symposium: Panel discussion on Tuesday, September 12, 2023, at 8:00 a.m. PT in San Diego, CA with Ellen Cahir-McFarland, Ph.D., Chief Scientific Officer. Morgan Stanley 21st Annual Global Healthcare Conference: Presentation on Monday, September 11, 2023, at 8:00 a.m. ET in New York, NY with Samantha Singer, M.S., M.B.A., President, and Chief Executive Officer. 2023 Cantor Global Healthcare Conference: Participating in 1x1 meetings on Wednesday, September 27, 2023, in New York, NY. About Abata Therapeutics Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. Abata’s lead programs are both in IND-enabling studies, beginning with its lead program in progressive multiple sclerosis (MS), and its second program in type 1 diabetes. Both indications are tissue-specific autoimmune diseases with substantial unmet needs, supporting a strong rationale for AbataAbata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Watertown, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information. View source version on businesswire.com: Contacts Media Cory Tromblee Scient PR cory@scientpr.com Investors Julie Seidel Stern Investor Relations, Inc. julie.seidel@sternir.com Source: Abata Therapeutics View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.